Kairos Pharma, LTD. SEC filings KAPA

Kairos Pharma, LTD. has 125 filings in SEC EDGAR's recent list, going back to Mar 29, 2023. Its latest annual report, Form ARS, was filed on May 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.

Kairos Pharma, LTD. SEC filings
Form Description Filed Period
EFFECT Filing Jan 23, 2026 —
CORRESP Letter to the SEC Jan 21, 2026 —
UPLOAD Letter from the SEC Jan 15, 2026 —
DEFR14A Filing May 16, 2025 —
PRER14A Filing May 6, 2025 —
EFFECT Filing Apr 24, 2025 —
CORRESP Letter to the SEC Apr 22, 2025 —
NT 10-K Filing Mar 28, 2025 Dec 31, 2024
EFFECT Filing Feb 4, 2025 —
CORRESP Letter to the SEC Jan 31, 2025 —
UPLOAD Letter from the SEC Jan 31, 2025 —
D Filing Jan 28, 2025 —
UPLOAD Letter from the SEC Jan 6, 2025 —
DRS Filing Jan 3, 2025 —
EFFECT Filing Sep 16, 2024 —
CORRESP Letter to the SEC Sep 13, 2024 —
CORRESP Letter to the SEC Sep 13, 2024 —
CORRESP Letter to the SEC Sep 13, 2024 —
CERT Nyse american certification Sep 12, 2024 —
8-A12B Filing Sep 12, 2024 —
CORRESP Letter to the SEC Sep 9, 2024 —
CORRESP Letter to the SEC Sep 9, 2024 —
CORRESP Letter to the SEC Jun 3, 2024 —
DRS/A Filing Sep 18, 2023 —
DRSLTR Filing Sep 15, 2023 —
UPLOAD Letter from the SEC Jul 6, 2023 —
DRSLTR Filing Jun 28, 2023 —
DRS/A Filing Jun 28, 2023 —
DRS/A Filing Jun 28, 2023 —
D Filing Apr 27, 2023 —
UPLOAD Letter from the SEC Apr 25, 2023 —
DRS Filing Mar 29, 2023 —

Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KAPA (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Los Angeles, CA
SEC filer status
, Emerging growth company
SEC CIK
1962011

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.